TY - JOUR
T1 - Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management
AU - Varone, Francesco
AU - Iovene, Bruno
AU - Sgalla, Giacomo
AU - Calvello, Mariarosaria
AU - Calabrese, Anna Chiara
AU - Larici, Anna Rita
AU - Richeldi, Luca
PY - 2020
Y1 - 2020
N2 - Fibrotic hypersensitivity pneumonitis is a complex interstitial lung disease that is not entirely understood. In its chronic and fibrotic form, hypersensitivity pneumonitis is one of the main mimickers of idiopathic pulmonary fibrosis (IPF). Distinguishing between these two conditions is challenging but is of particular clinical relevance. Two approved therapies are available for IPF, and a considerable number of clinical trials are now exploring newer pharmacological options. This impressive research effort is a consequence of new pathogenetic understanding, updated diagnostic criteria and a long history of pharmacological trials. Conversely, current knowledge gaps on pathogenesis of chronic hypersensitivity pneumonitis, coupled with lack of validated diagnostic criteria, make the management of this disease an unsolved clinical challenge. This also reflects the paucity of therapeutic clinical trials in this field. In this review, we describe the current evidence and the possible future options to approach this complex disease.
AB - Fibrotic hypersensitivity pneumonitis is a complex interstitial lung disease that is not entirely understood. In its chronic and fibrotic form, hypersensitivity pneumonitis is one of the main mimickers of idiopathic pulmonary fibrosis (IPF). Distinguishing between these two conditions is challenging but is of particular clinical relevance. Two approved therapies are available for IPF, and a considerable number of clinical trials are now exploring newer pharmacological options. This impressive research effort is a consequence of new pathogenetic understanding, updated diagnostic criteria and a long history of pharmacological trials. Conversely, current knowledge gaps on pathogenesis of chronic hypersensitivity pneumonitis, coupled with lack of validated diagnostic criteria, make the management of this disease an unsolved clinical challenge. This also reflects the paucity of therapeutic clinical trials in this field. In this review, we describe the current evidence and the possible future options to approach this complex disease.
KW - Antifibrotic treatment
KW - Exposures
KW - Immunosuppression
KW - Lung fibrosis
KW - Multidisciplinary management
KW - UIP-like pattern
KW - Antifibrotic treatment
KW - Exposures
KW - Immunosuppression
KW - Lung fibrosis
KW - Multidisciplinary management
KW - UIP-like pattern
UR - http://hdl.handle.net/10807/167666
U2 - 10.1007/s00408-020-00360-3
DO - 10.1007/s00408-020-00360-3
M3 - Article
SN - 0341-2040
VL - 198
SP - 429
EP - 440
JO - Lung
JF - Lung
ER -